New York Post
Trodelvy, in combination with Merck’s immunotherapy Keytruda, lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to new results…
Read More
Breast cancer risk cut by 35% in new clinical trial
Reuters
19:20
Trodelvy, in combination with Merck’s immunotherapy Keytruda, lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to new results…
